Skip to main content

MSRC Mass Spectrometry Research and Development

Peptide spectra in Wilms tumor that associate with adverse outcomes.

AUTHORS

Murphy AJAndrew Jackson , Pierce J Janene , Seeley EH Erin H , Sullivan LM Lisa M , Ruchelli ED Eduardo D , Nance ML Michael L , Caprioli RM Richard M , Lovvorn HN Harold N . The Journal of surgical research. 2015 6 15; 196(2). 332-8

ABSTRACT

The 2013 Children’s Oncology Group (COG) blueprint for renal tumor research challenges investigators to develop new, risk-specific biological therapies for unfavorable histology and higher-risk Wilms tumor (WT) in an effort to close a persistent survival gap and to reduce treatment toxicities. As an initial response to this call from the COG, we used imaging mass spectrometry to determine peptide profiles of WT associated with adverse outcomes.

The 2013 Children’s Oncology Group (COG) blueprint for renal tumor research challenges investigators to develop new, risk-specific biological therapies for unfavorable histology and higher-risk Wilms tumor (WT) in an effort to close a persistent survival gap and to reduce treatment toxicities. As an initial response to this call from the COG, we used imaging mass spectrometry to determine peptide profiles of WT associated with adverse outcomes.